

CSF tau and Delayed Primacy

RUNNING HEAD: CSF TAU AND DELAYED PRIMACY

The relationship between CSF tau markers, hippocampal volume and delayed primacy
performance in cognitively intact elderly individuals

Davide Bruno¹, Michel J. Grothe², Jay Nierenberg^{3,4}, Stefan J. Teipel^{2,5}, Henrik Zetterberg^{6,7},
Kaj Blennow⁶, & Nunzio Pomara^{3,4}

¹ Department of Psychology, Liverpool Hope University, Liverpool, UK

² German Center for Neurodegenerative Diseases (DZNE) – Rostock/Greifswald, Rostock,
Germany

³ Nathan Kline Institute for Psychiatric Research, Orangeburg, NY, USA

⁴ Department of Psychiatry, School of Medicine, New York University, New York City, NY,
USA

⁵ Department of Psychosomatic Medicine, University of Rostock, Rostock, Germany

⁶ Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of
Psychiatry and Neurochemistry, The Sahlgrenska Academy, University of Gothenburg, Mölndal,
Sweden

⁷ UCL Institute of Neurology, London, UK

CSF tau and Delayed Primacy

Corresponding Author:

Davide Bruno

Department of Psychology, Liverpool Hope University

Hope Park, Liverpool, L16 9JD

Phone: 0044 (0)151 2913832

Email: brunod@hope.ac.uk

Abstract

Background: Primacy performance in recall has been shown to predict cognitive decline in cognitively intact elderly, and conversion from mild cognitive impairment (MCI) to Alzheimer's disease (AD). Delayed primacy performance, but not delayed non-primacy performance, has been shown to be associated with hippocampal volume in cognitively intact older individuals. Since presence of neurofibrillary tangles is an early sign of AD-related pathology, we set out to test whether cerebrospinal fluid (CSF) levels of tau had an effect on delayed primacy performance, while controlling for hippocampal volume and CSF A β 1-42 levels.

Methods: Forty-seven individuals, 60 or older and cognitively intact, underwent a multi-session study including lumbar puncture, an MRI scan of the head and memory testing.

Results: Our regression analyses show that CSF levels of hyperphosphorylated (P) tau are only associated with reduced delayed primacy performance when hippocampal volumes are smaller.

Conclusion: Our findings suggest that hippocampal size may play a protective role against the negative effects of P tau on memory.

CSF tau and Delayed Primacy

Keywords

Serial Position; Primacy; Memory; Amyloid β 1-42; Tau; Hippocampus; Alzheimer's disease;

CSF Biomarkers.

Background

The identification of individuals at risk of AD during preclinical stages is critical for the implementation of early intervention strategies (1). Recently, episodic memory performance for primacy items (i.e., first few items on a study list) has been shown to provide predictive value for cognitive decline in both cognitively intact elderly (2), and conversion from MCI to AD (3). Primacy performance, especially in delayed memory tasks (e.g., after 20 minutes), is thought to reflect consolidation ability (4), a critical target function for prediction of subsequent neurodegeneration (5). Importantly, consolidation is thought to rely upon the hippocampal formation (6), whose integrity has also been examined in studies of AD prediction (e.g., 7-9). Finally, we have shown that hippocampal gray matter volume predicts delayed primacy performance, but not memory performance for other regions of the study list, in cognitively intact older individuals, thus confirming the link between hippocampus and memory for early list items (10).

A key component of AD neuropathology is the presence of neurofibrillary tangles, which are typically observed in the medial temporal lobe (MTL) first, and in the hippocampus in particular (11). The degree of neurofibrillary tangle burden has been associated with levels of total (T) and P tau in clinical-postmortem comparison studies (12-14, but see 15), suggesting that *in vivo* CSF levels of T and P tau may serve as surrogate measures for the degree of hippocampal and cortical neurofibrillary pathology. CSF levels of T and P tau have been found to associate with short term memory performance in AD (16), and to correlate negatively with hippocampal volume both in individuals with AD (17) and MCI (18). Moreover, P tau is considered a key factor in entorhinal cortex degeneration in cognitively intact participants (19).

For the reasons above, we set out to test whether delayed primacy performance – defined

CSF tau and Delayed Primacy

as the first four words on the study list to maintain consistency with (2) – in cognitively intact individuals is associated with CSF levels of T and P tau. In particular, we expect that higher levels of P tau, which may reflect tangle pathology (20) affecting the hippocampus and cortical brain areas, will be associated with poorer primacy performance. Moreover, we explore whether the relationship between hippocampal size and delayed primacy performance (10) is moderated by CSF tau levels, whilst controlling also for CSF levels of amyloid beta ($A\beta$) 1–42, which provide an index of amyloid pathology (e.g., 14).

Methods

Subjects. Participants for the study were either recruited from the Memory Education and Research Initiative (MERI) program at the Nathan Kline Institute for Psychiatric Research (NKI), or via advertisements; recruitment was originally for a study on major depression disorder (MDD) in old age (see 21). The study was approved by the institutional review boards of the Nathan Kline Institute for Psychiatric Research and the New York University School of Medicine. All participants were paid up to \$450.00 for their participation in the study, and provided formal consent prior to testing. A total of 133 participants were recruited for the study, although only 51 received a lumbar puncture from which CSF could be extracted. In order to maintain a cognitively intact sample, we excluded participants whose Mini-Mental State Examination (MMSE) score was below 28, and/or presented MRI evidence of confluent deep or periventricular white matter hyperintensities. These exclusion criteria left us with a total of 47 participants, 28 of whom received a diagnosis of MDD from a board-certified psychiatrist (NP), and 19 were controls.

CSF measurements. $A\beta$ 1–42 CSF levels were analysed with electrochemiluminescence technology using the MS6000 Human Ab Ultra-Sensitive Kit (Meso Scale Discovery,

CSF tau and Delayed Primacy

Gaithersburg, Md.). Both t and p Tau concentrations were determined using a sandwich enzyme-linked immunosorbent assay (ELISA) (Innotest hTAU-Ag, Innogenetics, Ghent, Belgium) specifically constructed for all tau isoforms, irrespective of phosphorylation status.

MRI Acquisition. The acquisition was performed on a 1.5 T Siemens Vision system (Erlangen, Germany) at the NKI. Images were acquired using a sagittal magnetization prepared rapid gradient-echo sequence [MPRAGE; repetition time (TR)/echo time (TE)=11.4/11.9 ms, 1 excitation, (NEX), matrix=256 x 256, FOV=307 mm, 1.2mm³ isotropic voxel, 172 slices, no gap]. Evaluation of white matter hyperintensities was performed using a fluid attenuated inversion recovery sequence [FLAIR; TR/TE=9000/119 ms, inversion time=2400 ms, NEX=1, matrix 256 x 256, FOV=240 mm, slice thickness=4 mm, 1 mm gap].

MRI preprocessing and analysis. MRI data processing followed procedures described previously (22-23). Figure 1 illustrates the hippocampal regions of interest (ROIs). The total intracranial volume (TIV) was used in the statistical model to account for differences in head size (see below), and was calculated as the sum of the total segmented gray matter, white matter and cerebrospinal fluid volumes in native space.

Insert Figure 1 here

Procedure. The study was conducted at the NKI and at the Clinical and Translational Science Institute, NYU, over multiple visits. On the first visit, after informed consent was provided, volunteers were administered a general medical intake questionnaire, and had their vital signs measured; the MMSE score and the Hamilton Depression Rating (HAM-D) score, which measures severity of current depressive symptoms, were obtained during this visit. On a second visit, participants received an MRI scan of the head. Neuropsychological testing took place on a third visit, and memory performance was assessed at this stage with the Buschke Selective

CSF tau and Delayed Primacy

Reminding Test (BSRT; 24). This test comprises a list of 16 unrelated nouns, presented orally to the participant at a rate of 2 seconds each. After presentation, participants were asked to freely recall as many items as possible, stopping once they feel no more items can be retrieved. In the delayed trial, which is the focus of our current examination (cf., 2), the free recall task occurs roughly after a 20-minute delay from the initial presentation.

During a fourth and final session, a lumbar puncture was performed under guided fluoroscopy. Participants were asked to fast overnight and the procedure took place between 9:00 and 10:00 in the morning. A total of 15 ml of clear CSF was collected in three polypropylene tubes labelled “A” (first 5 ml), “B” (second 5 ml), and “C” (third 5 ml). The tubes were immediately placed on ice for a maximum of 1 hour until the samples were centrifuged at 4°C (at 1500 rpm) for 10 minutes. Aliquots of 0.25 ml were subsequently placed into 1.00-ml polypropylene cryogenic vials and put into Nunc eight-cell storage boxes (Nalge Nunc International, Rochester, N.Y.) at –80°C. All A β and tau determinations were performed from tube “C”.

Study Design and Analysis. To test our hypothesis that P tau, either directly or via moderation with hippocampal gray matter volume, predicts delayed primacy performance, we carried out multiple linear regression analyses. The outcome variables, analyzed separately, were a) the proportion of primacy items (first four words; cf., 2) recalled in the delayed task of the BSRT task, and b) the proportion of non-primacy (all words recalled minus primacy words) items recalled in the same task. Both outcome variables were normally distributed based on assessment of skewness and kurtosis (25). The main predictor was CSF tau, either T or P in separate analyses to avoid multicollinearity (the correlation between T and P tau yielded an r coefficient of 0.968, $p < 0.001$). Moreover, we also tested the tau (both T and P) by hippocampal volume moderation term in a separate model. Age; CSF A β 1-42; total hippocampal volume (mm³); total

CSF tau and Delayed Primacy

intracranial volume (TIV; mm³) to control for head size; and HAM-D score to control for presence of current depressive symptoms, were used as control variables in a three-model procedure. Model 1 included all control variables, model 2 included the predictor, and model 3 included the moderation term. Finally, all predictors and control variables were standardized.

Insert Table 1 here

Results

Table 1 reports group demographics, CSF values and memory performance scores. The total N for T tau was 46 due to a missing value. No issues of multicollinearity were observed (variance inflation factor ≤ 2.628) in the regression analyses. Considering the mixed nature of our sample (i.e., individuals with MDD and controls), we evaluated the possibility that the HAM-D scores could be highly skewed (e.g., 0 values for all controls). However, visual exploration of the scores yielded no significant outliers, and z-scores for both skewness and kurtosis were within the typically accepted 1.96 threshold (≤ 1.80 ; 25).

P tau was a significant predictor of delayed primacy performance, $\beta = -.388$, $p = .022$, but this relationship appears to be qualified by the interaction between P tau and hippocampal size, $\beta = .354$, $p = .035$. The interaction brought explained variance (R^2) from 0.191 with model 1 and 2 combined to 0.280 with model 3, for a 32% increase. Figure 2 shows that delayed primacy performance is unaffected by changes in P tau CSF levels at larger hippocampal volumes, but declines when the P tau levels are higher and the size of the hippocampus is smaller. These results suggest that hippocampal size may provide a form of protection against increases in P tau CSF levels.

In contrast, neither P tau (only 0.009 variance explained over model 1), nor the moderation term (only 0.001 variance explained over model 2), nor any of the control variables appeared to

CSF tau and Delayed Primacy

predict delayed non-primacy performance significantly. The closest predictor in this analysis was A β 1-42, $\beta = .280$, $p = .090$, suggesting that higher levels of CSF A β 1-42, which should index less amyloid pathology, may be associated with better memory performance for non-primacy items.

Analogously to P tau, T tau showed marginal effects on delayed primacy both independently, $\beta = -.336$, $p = .078$, and as part of the interaction, $\beta = .315$, $p = .072$, although neither relationship is statistically significant. Also, once again, the closest significant predictor of non-primacy performance was CSF A β 1-42, $\beta = .279$, $p = .095$.

Insert Figure 2 here

Discussion

Recent findings have shown that delayed free recall performance for early-list words (i.e., delayed primacy performance) may be predictive of cognitive decline in older individuals who are cognitively intact at baseline (2); and that, also in cognitively healthy participants, hippocampal gray matter volume is associated with delayed primacy, but not delayed non-primacy, performance (10). These results are consistent with a burgeoning literature on the predictive and diagnostic value of serial position analysis, and primacy in particular (e.g., 3, 26-27). In this study on cognitively intact elderly individuals, we have demonstrated for the first time that delayed primacy performance is also affected by CSF levels of P tau. P tau is a marker of neurofibrillary pathology, which is considered to be one of the first neuropathological events in AD, and is thought to be initiated in the MTL, including the hippocampus. Critically, we observed in our study an interaction effect between hippocampal gray volume and CSF P tau levels on delayed primacy performance. This interaction suggests that hippocampal size may act as a protective factor against the deleterious effects of P tau on delayed primacy performance.

A limitation of our present study is that the sample was made up of both participants with a diagnosis of MDD and healthy controls. MDD has been associated with poorer memory performance (e.g., 28) and reduced hippocampal volume (e.g., 29), and it is therefore possible that the combination of healthy and depressed participants may have confounded our results. However, considering that we controlled for the HAM-D score in all of our analyses, we feel quite confident that depressive symptoms did not significantly alter the pattern of our results.

Another potential issue pertains to the possibility of a selection bias in CSF collection. As noted, out of 133 total participants, only 51 subjects consented to the lumbar puncture. The idea of having a lumbar puncture can be frightening, and all prospective participants are informed of the possible side-effects, such as bleeding and headaches. Therefore, it is not implausible that a systematic bias may be introduced in the study and that only certain participants (e.g., only highly motivated participants, or highly educated) may consent to the lumbar puncture. However, a basic comparison between consenters and non-consenters, showing no significant difference across groups in age, MMSE score or years of education ($p \geq .208$), provides no evidence of a bias, although this possibility cannot be categorically ruled out.

Attempts at investigating the relationship between hippocampal volume and episodic memory function in older adults have been met so far with high levels of variability across studies and little supporting evidence of a positive correlation between size and performance (30). Our results may help clarifying this issue. First of all, if the hippocampus is primarily involved with the retrieval of early list items, as suggested by Bruno et al. (10), then it is possible that studies that ignore serial position performance and focus exclusively on total list memory will find associations between hippocampal size and memory only when, incidentally, primacy and non-primacy outputs are highly correlated. For example, we can imagine three study

CSF tau and Delayed Primacy

participants: Participant A recalls all primacy items (e.g., 4) and all non-primacy items (e.g., 12) for a total of 16 items; Participant B recalls 0 primacy items, but all non-primacy items for a total of 12; and Participant C recalls all primacy items, but 0 non-primacy items for a total of 4. In this example, and based on our conjecture of a preferential link between hippocampus and primacy, Participant C would be expected to have a larger hippocampus than Participant B despite a lower total memory score; additionally, Participant A would be expected to have roughly a similar-sized hippocampus as Participant C, despite a much higher total score. This example illustrates how the issues of inter-study variability in examining the relationship between hippocampal volume and episodic memory ability may at least partly be related to differences in serial position effects.

An alternative solution to the issue of inconsistency across studies may be found in our current results. As Figure 2 suggests that smaller hippocampal volumes are only associated with a reduction of memory performance, specifically delayed primacy, in the presence of high levels of P Tau. Therefore, it may be possible that hippocampal function, and consequently memory function, are roughly comparable across a wide range of hippocampal volumes as long as these remain above a certain size that we can consider to be “normal”. In contrast, when hippocampal volumes are smaller, they are only good estimators of individual hippocampal dysfunction, and therefore poorer memory, when they are also accompanied by a neurodegenerative process, such as, for example, macrostructural hippocampal degeneration caused by neurofibrillary tangles. More research however is required to clarify these issues further.

References

1. Emery VOB. Alzheimer disease: are we intervening too late? *J Neural Transm* 2011; 118:1361-78.
2. Bruno D, Reiss PT, Petkova E, Sidtis JJ, Pomara N. Decreased Recall of Primacy Words Predicts Cognitive Decline. *Arch Clin Neuropsychol* 2013; 28: 95-103.
3. Egli SC, Beck IR, Berres M, Foldi NS, Monsch AU, Sollberger M. Serial position effects are sensitive predictors of conversion from MCI to Alzheimer's disease dementia. *Alzheimers Dement* 2014.
4. McGaugh JL. Memory: a century of consolidation. *Science* 2000; 287: 248-51.
5. Gomar JJ, Bobes-Bascaran MT, Conejero-Goldberg C, Davies P, Goldberg TE. Utility of combinations of biomarkers, cognitive markers, and risk factors to predict conversion from mild cognitive impairment to Alzheimer disease in patients in the Alzheimer's disease neuroimaging initiative. *Arch Gen Psychiat* 2011; 68:961-69.
6. Wixted JT. The psychology and neuroscience of forgetting. *Annu Rev Psychol* 2004; 55:235-69.
7. Apostolova LG, Mosconi L, Thompson PM, Green AE, Hwang KS, Ramirez A, Mistur R, Tsui WH, de Leon MJ. Subregional hippocampal atrophy predicts Alzheimer's dementia in the cognitively normal. *Neurobiol Aging* 2010; 31:1077-88.
8. Achterberg HC, van der Lijn F, den Heijer T, Vernooij MW, Ikram MA, Niessen WJ, de Bruijne M. Hippocampal shape is predictive for the development of dementia in a normal, elderly population. *Hum Brain Mapp* 2014; 35:2359-71.
9. Tondelli M, Wilcock GK, Nichelli P, De Jager CA, Jenkinson M, Zamboni G. Structural MRI changes detectable up to ten years before clinical Alzheimer's disease. *Neurobiol*

Aging 2012; 33:825-e25.

10. Bruno D, Grothe MJ, Nierenberg J, Teipel S, Pomara N. Hippocampal size predicts delayed primacy performance in cognitively intact elderly participants. Poster presented at the Alzheimer's Association International Conference, Copenhagen, Denmark 2014.
11. Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol* 1991; 82: 239-59.
12. Buerger K, Ewers M, Pirttilä T, Zinkowski R, Alafuzoff I, Teipel SJ, DeBernardis J, Kerkman D, McCulloch C, Soininen H, Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. *Brain* 2006; 129:3035-41.
13. Tapiola T, Overmyer M, Lehtovirta M, Helisalml S, Ramberg J, Alafuzoff I, Riekkinen P, Soininen H. The level of cerebrospinal fluid tau correlates with neurofibrillary tangles in Alzheimer's disease. *Neuroreport* 1997; 8: 3961-63.
14. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T. Cerebrospinal fluid β -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. *Arch Neurol* 2009; 66: 382-89.
15. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin J, Vanmechelen E, Van Broeckhoven C, De Deyn PP. No association of CSF biomarkers with APOE ϵ 4, plaque and tangle burden in definite Alzheimer's disease. *Brain* 2007; 130: 2320-26.
16. Lin YT, Cheng JT, Yao YC, Lo YK, Lin CH, Ger LP, Lu PJ. Increased Total TAU But Not Amyloid- β $\{42\}$; in Cerebrospinal Fluid Correlates with Short-Term Memory Impairment in Alzheimer's Disease. *J Alzheimers Dis* 2009; 18:907-18.

17. De Souza LC, Chupin M, Lamari F, Jardel C, Leclercq D, Colliot O, Lehericy S, Dubois B, Sarazin, M. CSF tau markers are correlated with hippocampal volume in Alzheimer's disease. *Neurobiol Aging* 2012; 33:1253-57.
18. Herukka SK, Pennanen C, Soininen H, Pirttilä T. CSF A β 42, tau and phosphorylated tau correlate with medial temporal lobe atrophy. *J Alzheimers Dis* 2008; 14:51-57.
19. Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM. Amyloid- β associated volume loss occurs only in the presence of phospho-tau. *Annals Neurol* 2011; 70:657-61.
20. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. *Nat Rev Neurol* 2010; 6:131-44.
21. Pomara N, Bruno D, Sarreal A, Hernando R, Nierenberg J, Petkova E, Sidtis JJ, Mehta PD, Wisniewski TM, Pratico D, Zetterberg H, Blennow K. Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder. *Am J Psychiatry* 2012; 169:523-30.
22. Grothe MJ, Ewers M, Krause B, Heinsen H, Teipel SJ. Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. *Alzheimers Dement* 2014.
23. Grothe MJ, Schuster C, Bauer F, Heinsen H, Prudlo J, Teipel SJ. Atrophy of the cholinergic basal forebrain in dementia with Lewy bodies and Alzheimer's disease dementia. *J Neurol In Press*.
24. Buschke H, Fuld PA. Evaluating storage, retention, and retrieval in disordered memory and learning. *Neurol* 1974; 24:1019-19.
25. Kim HY. Statistical notes for clinical researchers: assessing normal distribution using skewness and kurtosis. *Restor Dent Endod* 2013; 38:52-54.

26. Howieson DB, Mattek N, Seeyle AM, Dodge HH, Wasserman D, Zitzelberger T, Jeffrey K. Serial position effects in mild cognitive impairment. *J Clin Exp Neuropsychol* 2011; 33:292-99.
27. La Rue A, Hermann B, Jones JJ, Johnson S, Ashtana S, Sager MA. Effect of parental family history of Alzheimer's disease on serial position profiles. *Alzheimers Dement*, 2008; 4:285-90.
28. Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. *Brit J Psychiat* 2001; 178:200-06.
29. Bremner JD, Narayan M, Anderson ER, Staib LH, Miller HL, Charney DS. Hippocampal volume reduction in major depression. *Am J Psychiat* 2000; 157:115-18.
30. Van Petten C. Relationship between hippocampal volume and memory ability in healthy individuals across the lifespan: review and meta-analysis. *Neuropsychologia* 2004; 42:1394-13.

CSF tau and Delayed Primacy

Funding and Conflict of Interest

This study was funded in part by an NIMH grant (R01 MH-080405) to NP. No conflict of interest to declare.

Acknowledgments

We wish to thank Marina Boccardi for expert advice and quality check of the traced hippocampus outlines following the EADC-ADNI harmonized hippocampus protocol, as well as Luigi Antelmi for helping with format conversion of the traced hippocampus mask. We would also like to acknowledge the help and support provided by Chelsea Reichert, Dr Antero Sarreal and Dr Hernando Raymundo. We also wish to thank Jeremy Dawson for making available online resources to plot simple slope effects (<http://www.jeremydawson.com/slopes.htm>).

CSF tau and Delayed Primacy

Table 1. Demographics, CSF values and memory performance: Number of subjects (i.e., N); Age in years (mean and standard deviation); HDS score (mean and standard deviation); CSF levels of A β 1-42, T and P tau (mean and standard deviation); and proportions of primacy and non-primacy performance (mean and standard deviation).

N	47
Age	67.13 (6.23)
HDS	10.55 (11.01)
A β 1-42	269.45 (158.93)
T tau	296.02 (132.38)*
P tau	50.00 (23.78)
Primacy	0.64 (0.27)
Non-primacy	0.54 (0.17)

** Due to an undetermined value, the N for T tau is 46.*

CSF tau and Delayed Primacy

Figure 1. Hippocampal ROIs in Montreal Neurological Institute space.

Figure 2. Plot of CSF P tau levels (X-axis) by proportion of delayed recalled primacy items (Y-axis), as moderated by hippocampal gray matter volume.

Figure 1.




Figure 2.

